Related Experiment Video
Updated: Jul 9, 2026
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents
M V Ramana Reddy1, Muralidhar R Mallireddigari, Stephen C Cosenza
1Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, Pennsylvania 19140-5101, USA. rreddy@temple.edu
Abstract:
Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of "checkpoints" governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls, and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, we describe the synthesis and SAR of a novel group of cytotoxic molecules that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity, and drug resistance suggest potential for use of these agents in cancer therapy.
Insights
Researchers developed novel cytotoxic molecules that halt normal cell growth in G1 phase while arresting tumor cells in mitosis, selectively killing cancer cells without harming healthy cells. This offers a promising new avenue for cancer therapy.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Cell cycle progression relies on cyclins and cyclin-dependent kinases, with checkpoints regulating phase transitions.
- Tumor development often involves the loss of these critical cell cycle checkpoint controls.
- Targeting these aberrant controls presents a therapeutic strategy for selective cancer cell elimination.
Purpose of the Study:
- To synthesize and characterize novel cytotoxic molecules.
- To investigate the selective effects of these molecules on normal versus tumor cells.
- To evaluate the potential of these agents in cancer therapy.
Main Methods:
- Synthesis of a novel group of cytotoxic molecules.
- Structure-Activity Relationship (SAR) studies.
- In vitro and in vivo (xenograft models) evaluation of antitumor activity and toxicity.
Main Results:
- Molecules selectively induce G1 phase arrest in normal cells.
- Molecules induce mitotic arrest in tumor cells, leading to selective tumor cell death.
- Demonstrated broad-spectrum antitumor activity in vitro and in xenograft models.
- Exhibited lack of in vivo toxicity and potential to overcome drug resistance.
Conclusions:
- The novel cytotoxic agents show selective tumor cell killing by differential cell cycle arrest.
- These compounds possess broad-spectrum antitumor potential with a favorable safety profile.
- The findings suggest significant promise for these agents in clinical cancer therapy.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase